EP1102786A4 - Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments - Google Patents
Low adenosine anti-sense oligonucleotide agent, composition, kit and treatmentsInfo
- Publication number
- EP1102786A4 EP1102786A4 EP99939006A EP99939006A EP1102786A4 EP 1102786 A4 EP1102786 A4 EP 1102786A4 EP 99939006 A EP99939006 A EP 99939006A EP 99939006 A EP99939006 A EP 99939006A EP 1102786 A4 EP1102786 A4 EP 1102786A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatments
- kit
- composition
- sense oligonucleotide
- oligonucleotide agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9521298P | 1998-08-03 | 1998-08-03 | |
US95212P | 1998-08-03 | ||
PCT/US1999/017712 WO2000009525A2 (en) | 1998-08-03 | 1999-08-03 | Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1102786A2 EP1102786A2 (en) | 2001-05-30 |
EP1102786A4 true EP1102786A4 (en) | 2002-03-06 |
Family
ID=22250687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99939006A Withdrawn EP1102786A4 (en) | 1998-08-03 | 1999-08-03 | Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1102786A4 (en) |
CN (1) | CN1317009A (en) |
AU (1) | AU5337499A (en) |
CA (1) | CA2333901A1 (en) |
HK (1) | HK1042706A1 (en) |
WO (1) | WO2000009525A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7034007B1 (en) | 1995-06-07 | 2006-04-25 | East Carolina University | Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion |
US6825174B2 (en) | 1995-06-07 | 2004-11-30 | East Carolina University | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
EP1165123A4 (en) * | 1999-03-26 | 2002-09-11 | Human Genome Sciences Inc | 48 human secreted proteins |
AU3766900A (en) * | 1999-03-26 | 2000-10-16 | Human Genome Sciences, Inc. | 47 human secreted proteins |
JP2003515525A (en) * | 1999-04-06 | 2003-05-07 | イースト カロライナ ユニバーシティ | Low adenosine antisense oligonucleotides, compositions, kits and methods for treating airway disorders associated with bronchoconstriction, pneumonia, allergy and surfactant depletion |
US6489151B1 (en) * | 2000-03-27 | 2002-12-03 | The Research Foundation Of State University Of New York | Biologically active alternative form of the IKKα IκB kinase |
DE10019252A1 (en) * | 2000-04-18 | 2001-10-31 | Klaus Karl Degitz | Polydeoxyribonucleotides to inhibit ICAM-1 gene expression |
DE10049549A1 (en) * | 2000-10-06 | 2002-05-02 | Markus Hecker | Inhibitor of the transcription factor IFR-1, useful for treating e.g. transplant rejection and autoimmune disease, reduces expression of CD40 |
PT1406667E (en) * | 2001-07-06 | 2008-05-23 | Topigen Pharmaceuticals Inc | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
US20060088835A1 (en) * | 2002-04-05 | 2006-04-27 | Pickard Benjamin S | Schizophrenia associated genes |
AR040996A1 (en) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
CN1322899C (en) * | 2004-02-11 | 2007-06-27 | 中国科学院上海生命科学研究院 | Anti cancer gene medicinal composition, micromolecule interfere RNA and its screening method |
MX2007005083A (en) | 2004-10-29 | 2007-10-03 | Topigen Pharmaceuticals Inc | Antisense oligonucleotides for treating allergy and neoplastic cell proliferation. |
CN101443357A (en) | 2005-08-12 | 2009-05-27 | 先灵公司 | MCP1 fusions |
US8524217B2 (en) | 2010-05-11 | 2013-09-03 | Merck Sharp & Dohme Corp. | MCP1-Ig fusion variants |
US10017762B2 (en) * | 2010-11-24 | 2018-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for treating or preventing lupus |
PL2643460T3 (en) * | 2011-06-15 | 2018-01-31 | Grifols Therapeutics Inc | Methods, compositions, and kits for determining human immunodeficiency virus (hiv) |
CN102866153B (en) * | 2012-09-29 | 2014-08-13 | 郑州安图生物工程股份有限公司 | Prostatitis joint-detection kit |
KR20150126048A (en) * | 2013-03-11 | 2015-11-10 | 유니버시티 오브 노스캐롤라이나 앳 채플 힐 | Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing |
EP4237436A2 (en) * | 2020-10-29 | 2023-09-06 | Mariano A. Garcia-Blanco | Soluble interleukin-7 receptor (sil7r) modulating therapy to treat cancer |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010820A1 (en) * | 1991-11-26 | 1993-06-10 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
WO1993012756A2 (en) * | 1991-12-17 | 1993-07-08 | The Regents Of The University Of California | Transfection of lung via aerosolized transgene delivery |
WO1995035032A1 (en) * | 1992-05-22 | 1995-12-28 | The Scripps Research Institute | SUPPRESSION OF NUCLEAR FACTOR-kB DEPENDENT PROCESSES USING OLIGONUCLEOTIDES |
WO1996040162A1 (en) * | 1995-06-07 | 1996-12-19 | East Carolina University | Method of treatment for lung diseases using antisense oligonucleotides |
WO1998011211A2 (en) * | 1996-09-10 | 1998-03-19 | Hybridon, Inc. | METHOD FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES |
WO1999060166A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for the pulmonary delivery of nucleic acids |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5932557A (en) * | 1997-08-12 | 1999-08-03 | Mustafa; S. Jamal | Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments |
-
1999
- 1999-08-03 WO PCT/US1999/017712 patent/WO2000009525A2/en active Search and Examination
- 1999-08-03 CA CA002333901A patent/CA2333901A1/en not_active Abandoned
- 1999-08-03 CN CN99809303A patent/CN1317009A/en active Pending
- 1999-08-03 EP EP99939006A patent/EP1102786A4/en not_active Withdrawn
- 1999-08-03 AU AU53374/99A patent/AU5337499A/en not_active Abandoned
-
2002
- 2002-04-08 HK HK02102614.0A patent/HK1042706A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010820A1 (en) * | 1991-11-26 | 1993-06-10 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
WO1993012756A2 (en) * | 1991-12-17 | 1993-07-08 | The Regents Of The University Of California | Transfection of lung via aerosolized transgene delivery |
WO1995035032A1 (en) * | 1992-05-22 | 1995-12-28 | The Scripps Research Institute | SUPPRESSION OF NUCLEAR FACTOR-kB DEPENDENT PROCESSES USING OLIGONUCLEOTIDES |
WO1996040162A1 (en) * | 1995-06-07 | 1996-12-19 | East Carolina University | Method of treatment for lung diseases using antisense oligonucleotides |
WO1998011211A2 (en) * | 1996-09-10 | 1998-03-19 | Hybridon, Inc. | METHOD FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES |
WO1999060166A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for the pulmonary delivery of nucleic acids |
Non-Patent Citations (7)
Title |
---|
LOAKES D ET AL: "5-NITROINDOLE AS AN UNIVERSAL BASE ANALOGUE", NUCLEIC ACIDS RESEARCH, vol. 22, no. 20, 1994, pages 4039 - 4043, XP000999195, ISSN: 0305-1048 * |
METZGER W JAMES ET AL: "Oligonucleotide therapy of allergic asthma.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 104, no. 2 PART 1, August 1999 (1999-08-01), pages 260 - 266, XP001024505, ISSN: 0091-6749 * |
NARAYANAN, R.: "The NK-kappaB transcription factor", STEIN, C.A. & KRIEG, A.M. 'APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY'. WILEY-LISS, NEW YORK, US; 1998; CHAPTER 12, pages 231 - 243, XP002185125 * |
NICHOLS R ET AL: "A UNIVERSAL NUCLEOSIDE FOR USE AT AMBIGOUS SITES IN DNA PRIMERS", NATURE, vol. 369, no. 6480, 9 June 1994 (1994-06-09), pages 492 - 493, XP000560346, ISSN: 0028-0836 * |
OHTSUKA E ET AL: "AN ALTERNATIVE APPROACH TO DEOXYOLIGONUCLEOTIDES AS HYBRIDIZATION PROBES BY INSERTION OF DEOXYINOSINE AT AMBIGUOUS CODON POSITIONS", JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), vol. 260, no. 5, 10 March 1985 (1985-03-10), pages 2605 - 2608, XP002031938 * |
RAHMAN M SAYEEDUR ET AL: "Nebularine (9-2'-deoxy-beta-D-ribofuranosylpurine) has the template characteristics of adenine in vivo and in vitro.", MUTATION RESEARCH, vol. 377, no. 2, 1997, pages 263 - 268, XP001024479, ISSN: 0027-5107 * |
See also references of WO0009525A3 * |
Also Published As
Publication number | Publication date |
---|---|
CA2333901A1 (en) | 2000-02-24 |
WO2000009525A3 (en) | 2000-05-18 |
HK1042706A1 (en) | 2002-08-23 |
CN1317009A (en) | 2001-10-10 |
AU5337499A (en) | 2000-03-06 |
EP1102786A2 (en) | 2001-05-30 |
WO2000009525A2 (en) | 2000-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1102786A4 (en) | Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments | |
AP2000002015A0 (en) | Pyrrolo¬2,3d¾pyrimidine compositions and their use | |
ZA994141B (en) | Conditioning detergent composition and use. | |
HUP0003364A3 (en) | Quinoline-indole antimicrobial agents, uses and compositions related thereto | |
IL189430A0 (en) | 13-membered azalides and their use as antibiotic agents | |
GB9813271D0 (en) | Composition and use | |
HK1034722A1 (en) | Antipicornaviral compounds, their preparation and use | |
AU7124398A (en) | Biflavinoids and derivatives thereof as antiviral agents, alone or in combination with at least one known antiviral agent | |
HUP0103845A2 (en) | Disinfecting composition and its use | |
GB9817235D0 (en) | Compound,composition and use | |
GB2324727B (en) | Antimicrobial compositions, their preparation and use | |
HK1031725A1 (en) | 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use | |
HUP0102808A3 (en) | Ectoparasiticide agents | |
GB9817236D0 (en) | Compound,composition and use | |
GB0026467D0 (en) | Compound, composition and use | |
HK1042847A1 (en) | Bone-pathobolism treating agent | |
GB9903447D0 (en) | Compound, composition and use | |
HUP0104350A3 (en) | Synergetic fungicidal composition comprising thieno[2,3-d]pyrimidin-4-one and its use | |
ZA200006020B (en) | Voacamine as anti-malarial agent and anti-malarial agent containing voacamine. | |
AU6459199A (en) | Antisense oligonucleotides which inhibit telomerase's activity and their uses | |
AU2001240098A1 (en) | 4'-thio-l-xylo furanosyl nucleosides, precursors thereof, preparation and use thereof | |
GB9817238D0 (en) | Compound,composition and use | |
GB9917593D0 (en) | Compound, composition, process and use | |
GB9820631D0 (en) | Hair treatment composition, method and use | |
SI1043306T1 (en) | 3-amino-3-arylpropan-1-ol-derivates, their preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010205 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 6/00 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020121 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
DA4 | Supplementary search report drawn up and despatched (deleted) | ||
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20020424 |
|
17Q | First examination report despatched |
Effective date: 20040223 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040706 |